Wednesday, September 30th | 13 Tishri 5781

Subscribe
September 16, 2020 10:08 am

Israel’s Betalin Therapeutics Plans IPO to Fund Diabetes Trials

avatar by Reuters and Algemeiner Staff

Illustrative. Photo: Wikimedia Commons.

Israel’s Betalin Therapeutics is preparing an initial public offering that will value the biotech firm between $150-170 million to fund trials for its diabetes treatment, the company’s chief executive said on Wednesday.

Betalin is developing an artificial micro-pancreas that is implanted in the thigh of diabetics to help control the level of sugar in their blood. The system mimics the function of a healthy pancreas by secreting insulin and making daily injections unnecessary, said CEO Nikolai Kunicher.

The company, which is funded by private investors, is looking to raise about $40 million in an IPO in New York or London by the end of next year.

In the past year it won 5.5 million euros ($6.52 million) in grants from Europe’s Horizon 2020 research and innovation program.

Related coverage

September 30, 2020 3:28 pm
0

US Army Receives First Iron Dome Aerial Defense Battery From Israel

Israel delivered on Wednesday the first of two Iron Dome aerial defense batteries purchased last year by the US Army. "These...

“By the end of next year we are planning to start clinical trials,” Kunicher said. “We will need to raise funds for the completion of phase 2 and phase 3 clinical trials.”

The technology uses healthy donor cells that secrete insulin. Those cells are planted on a thin scaffold made out of tissue from pig lungs.

One of its advantages, Kunicher said, is that the implant process is relatively simple and done under local anesthesia.

Should the trials go smoothly, a final product is still some five years off, he said.

People with diagnosed diabetes have about 2.3 times higher medical expenditures, of which about $9,601 is attributed directly to the disease each year, according to the American Diabetes Association.

Betalin said its treatment will have a one-time cost of about $50,000.

Share this Story: Share On Facebook Share On Twitter

Let your voice be heard!

Join the Algemeiner

Algemeiner.com

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.